Raloxifene Hydrochloride
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods).
Anti Estrogen Powder Keoxifene Raloxifene Hydrochloride CAS 82640-04-8 Powder Anti Cancer
Details:
English name: Raloxifene hydrochloride
English Synonyms: Raloxifene hydrochloride; Evista; Keoxifene hydrochloride; LY 156758; Raloxifene HCl;
CAS: 82640-04-8
Formula: C28H29NO4S
MW: 475.5992
Molecular Structure:
Density: 1.285g / cm3
Boiling point: 687.5 ° C at 760 mmHg
Flash Point: 369.6 ° C
Vapor Pressure: 1.56E-19mmHg at 25 ° C
Assay:99%
Appearance:light yellow powder
Use:antineoplastic
Specification:
| ITEMS | SPECIFICATION | RESULT | |
| Characters | |||
| Appearance | White &off-white powder | Conform | |
|
Solubility |
Soluble in 10% sodium hydroxide solution. Slightly Soluble in methanol. Insoluble in water |
Conform |
|
| Identifications | Infrared Absorption | Conform | |
| Chloride | Conform | ||
| Tests
|
Loss on drying | ≤0.5% | 0.4% |
| Residue on ignition | ≤0.1% | 0.06% | |
| Heavy metals | ≤10ppm | Conform | |
|
RRelated substances
|
Raloxifene Impurity1 | ≤0.20 % | 0.10% |
| Any unspecified individual impurity 2
|
≤0.10% | Max. 0.08% | |
| Total impurities | ≤0.50% | 0.40% | |
| Assay | Raloxifene HCl | ≥98.0% | 99.0% |
Description:
Evista (Raloxifene Hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of Raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).
(1) Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. Raloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.
(2) Raloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.
Applications:
May prevent or treat corticosteroid-induced bone loss .American College of Rheumatology states that raloxifene can be offered to selected postmenopausal corticosteroid-treated women who refuse hormone replacement therapy or other antiresorptive agents (e.g., bisphosphonates, calcitonin) or in whom such therapies are contraindicated.
Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.
Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive breast cancer (STAR trial).No effect on the risk of lobular carcinoma in situ or ductal carcinoma in situ (STAR trial).Effect on breast cancer incidence in women with BRCA1 or BRCA2 genetic mutations not established.
Use and Dose:
Evista is specifically approved for the treatment and prevention of osteoporosis in postmenopausal women, the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. Evista is supplied as a 60 mg tablet designed for oral administration. The recommended initial dose of the drug is one 60 mg tablet daily, which may be administered any time of day without regard to meals.
Contact Now
Contact Now
Testolactone
Testolactone is a synthetic antineoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Despite some similarity to testosterone, testolactone has no in vivo androgenic effect.
Toremifene Citrate
Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body.
Raloxifene Hydrochloride
Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods).
DL-Aminoglutethimide
Aminoglutethimide is an adrenal steroid inhibitor. It works by blocking the production of a variety of hormones, including glucocorticoids, mineralocorticoids, estrogens, and androgens and is clinically used in the Treating Cushing syndrome and metastatic breast cancer. Aminoglutethimide is also used by body builders.
Formestane
Formestane is a synthetic steroidal substance with antineoplastic activity. Formestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens.
Mesterolone
Mesterolone is an orally applicable androgen, and DHT derivative,is sold under the brand proviron, In the late 70's and early 80'sMestero lone was used with some success in controlled studies ofmen suffering from various forms of depression.
Letrazole (Femara / Formestane)
emara (letrozole) is a type II (non-steroidal) third generation aromatase inhibitor.
Anastrozole (Arimidex)
Anastrozole is also called Arimidex. It is a type of hormone therapy called an aromatase inhibitor. Anastrozoles treats breast cancer in women who have had their menopause.
Exemestane (Aromasin)
Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to it for completion of a total of five consecutive years of adjuvant hormonal therapy.
Clomiphene Citrate (Clomid)
Clomifene or clomiphene (trademarked as Androxal, Clomid and Omifin, citrate salt Serophene) is a selective estrogen receptor modulator (SERM) that has become the most widely prescribed drug for ovulation induction to reverse anovulation or oligoovulation.
Tamoxifen Citrate (Nolvadex)
Nolvadex (tamoxifen citrate) is very comparable to Clomid, behaves in the same manner in all tissues, and is a mixed estrogen agonist/antagonist of the same type as Clomid.